SCHEMBL79802

SCHEMBL79802

NC(=O)Nc1cccc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 1.00
GAA P10253 2/20 1.00
ALDH1A1 P00352 2/20 0.72
POLB P06746 2/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
RAB9A P51151 4/20 0.65
NPC1 O15118 3/20 0.65
CYP1A2 P05177 1/20 0.65
CYP3A4 P08684 1/20 0.65
CYP2D6 P10635 1/20 0.65
CYP2C9 P11712 1/20 0.65
CYP2C19 P33261 1/20 0.65
MAPT P10636 2/20 0.62
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
SIGMAR1 Q99720 2/20 0.59
GRIN2D O15399 1/20 0.59
GRIN3B O60391 1/20 0.59
GRIN1 Q05586 1/20 0.59
GRIN2A Q12879 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrogen Sulfide SCHEMBL27471544 0.98 KDM4E (0.96) KDM4EGAAALDH1A1POLBSMN1; SMN2
Trimethylammonium SCHEMBL27855504 0.93 KDM4E (0.86) KDM4EGAAALDH1A1POLBSMN1; SMN2
Piperazine SCHEMBL25235944 0.89 KDM4E (0.80) KDM4EGAAALDH1A1POLBSMN1; SMN2
SCHEMBL6476396 0.89 KDM4E (0.79) KDM4EGAAALDH1A1POLBSMN1; SMN2
SCHEMBL27933369 0.87 KDM4E (0.77) KDM4EGAAALDH1A1POLBSMN1; SMN2
SCHEMBL1600584 0.86 KDM4E (0.76) KDM4EGAAALDH1A1POLBSMN1; SMN2
Piperidine SCHEMBL29006137 0.85 KDM4E (0.73) KDM4EGAAALDH1A1POLBSMN1; SMN2
SCHEMBL30393282 0.85 KDM4E (0.82) KDM4EGAAALDH1A1POLBSMN1; SMN2
SCHEMBL1276481 0.85 KDM4E (0.82) KDM4EGAAALDH1A1POLBSMN1; SMN2
SCHEMBL11291466 0.85 NPC1 (0.79) KDM4EGAAALDH1A1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1749 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4079303-B1 NAPHTHYLUREA COMPOUND FOR TREATING CORNEAL NEOVASCULAR DISEASE SUZHOU RAYMON PHARMACEUTICALS COMPANY LTD (CN) 2026-02-04 EP claimed
EP-4635495-A1 USE OF NAPHTHYLUREA COMPOUNDS IN PREPARATION OF DRUGS FOR TREATING PTERYGIUM Suzhou Raymon Pharmaceuticals Company, Ltd. (CN) 2025-10-22 EP claimed
US-12440480-B2 Use of naphthylurea compound SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD. (CN) 2025-10-14 US claimed
CN-119859278-A Naphthizimide modified magnetic nanoparticle for iron ion fluorescence detection and preparation method thereof 江苏海洋大学 2025-04-22 CN claimed
CN-116178248-B Naphthyl urea-piperidine compounds, and preparation method and application thereof 河南省锐达医药科技有限公司 2024-10-18 CN claimed
WO-2024124411-A1 USE OF NAPHTHYLUREA COMPOUNDS IN PREPARATION OF DRUGS FOR TREATING PTERYGIUM 苏州锐明新药研发有限公司 2024-06-20 WO claimed
CN-116731551-B Environment-friendly paint remover for aviation use and preparation method and application thereof 广东润和新材料科技有限公司 2024-06-04 CN claimed
EP-4373520-A1 COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING CORONAVIRUS VARIANT INFECTIONS AND METHODS OF USING THE SAME EnGeneIC Molecular Delivery Pty Ltd. (AU) 2024-05-29 EP claimed
CN-118065173-A Temperature regulating auxiliary agent for double-color erasable thermosensitive paper, and preparation method and application thereof 湖南鼎一致远科技发展股份有限公司 2024-05-24 CN claimed
CN-117263851-A Pyridine-naphthyl urea-piperazine derivative, and preparation method and application thereof 河南省锐达医药科技有限公司 2023-12-22 CN claimed
WO-1991012009-A1 USE OF SURAMIN TO TREAT RHEUMATOLOGIC DISEASES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) 1991-08-22 WO claimed
US-4692400-A CONTAINING A UREIDO- AND ACYLAMINO-CONTAINING PHENOL-TYPE CYAN COUPLER AND NEGATIVE-TYPE CORESHELL SILVER HALIDE GRAINS KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1987-09-08 US claimed
EP-0102821-B1 SILVER HALIDE COLOR PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL KONICA CORPORATION (JP) 1987-04-08 EP claimed
EP-0204416-A2 Light-sensitive silver halide color photographic material KONICA CORPORATION (JP) 1986-12-10 EP claimed
EP-0201027-A2 Silver halide photographic light-sensitive material KONICA CORPORATION (JP) 1986-11-12 EP claimed
US-4594314-A Containing phenol-type cyan coupler KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1986-06-10 US claimed
EP-0102821-A1 Silver halide color photographic light-sensitive material KONICA CORPORATION (JP) 1984-03-14 EP claimed
US-4292238-A Alkylation of benzthiazole-azo-phenylamine dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1981-09-29 US claimed
US-4021428-A 4-Piperidino-5-oxo-2-pyrazolines FUJI PHOTO FILM CO., LTD. (JA) 1977-05-03 US claimed
US-3956339-A 4-Pyridinio-5-pyrazolone salts, process for their preparation and their use FUJI PHOTO FILM CO., LTD. (JA) 1976-05-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12440480-B2 Use of naphthylurea compound UACA, CRYAA, VEGFA KDM4E 4231/4885GAA 394/4885ALDH1A1 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.